Wilbert van Workum contributes his experience in development and licensing of products and services in the area of next-generation sequencing and (onco)genetics. He co-founded and held management positions in several companies in the Life Science area, among which Bioké B.V., GenomeScan B.V. and Limes Innovations B.V.. Wilbert holds a Ph.D. degree in Molecular Biology (1997) from Leiden University, and is currently also CEO of Limes Innovations B.V..
Jeroen de Ridder holds a Ph.D. degree in Computer Science (2010) from Delft University of Technology and the Netherlands Cancer Institute. He leads a research group of ~12 researchers in the field of bioinformatics for health and disease. More specifically, his lab focuses on creating and applying innovative data science methods to advance the understanding of disease biology. His research efforts are always inspired by a biological question and typically deal with big data, such as large-scale genomics and epigenomics datasets. As a result, much of his research is based on machine learning and data integration algorithms and heavily relies on high-performance computing and statistics.
As of January 2019, Jeroen has joined the Oncode Institute to further contribute to improving molecular oncology and personalised cancer care.
Wigard Kloosterman holds a Ph.D. in Molecular Biology (2007) from Utrecht University. Until 2019, he was an Associate Professor at the Department of Genetics at the University Medical Center Utrecht, leading a research group in cancer genomics, with particular focus on understanding complex genomic variants and their contribution to cancer phenotypes, such as drug response. He contributed to bringing knowledge from cancer genomics research to the clinic. Furthermore, Dr Kloosterman is a leading expert in genome sequencing technology, including computational analysis, and he has contributed multiple seminal papers in this field. He is at the forefront of implementing third-generation nanopore sequencing technology in research and clinical settings. Besides his role within Cyclomics, Dr. Kloosterman is appointed as CSO of Frame Cancer Therapeutics, an immunotherapy start-up in Amsterdam, aiming for development of personalised cancer vaccines.
Alessio Marcozzi holds a Ph.D. in Molecular Biology (2015) from Groningen University. Formerly employed by the University Medical Center Utrecht as a postdoctoral scientist, he worked in the Department of Genetics under the lead of Dr. Kloosterman. Now, he is full-time-appointed Principal Scientist at Cyclomics. His current efforts are focused on the R&D and product development of new methods for sequencing-based cancer diagnostics. Other areas of interest and proven expertise are in vitro evolution, genetic engineering, and bioinformatics.
Martin Elferink holds a Ph.D. in Molecular Biology (2011) from the Wageningen University. Currently, he is employed by the University Medical Center Utrecht as a postdoctoral scientist under the lead of Prof. Dr. Hans Kristian Ploos van Amstel. He works in the section Genome Diagnostics within the Department of Genetics. His current research is focused on innovation and implementation of novel bioinformatics approaches into clinical patient care.